Remote glucose monitoring is feasible for patients and providers using a commercially available population health platform

Frontiers in Endocrinology

Endocrinology

Carrie Lewis¹  Crystal C. Romero²  Nicole S. Glaser²  Stephanie S. Crossen³ 

[1] Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA, United States;Department of Pediatrics, University of California Davis, Sacramento, CA, United States;Department of Pediatrics, University of California Davis, Sacramento, CA, United States;Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA, United States;

关键词: remote patient monitoring;    type 1 diabetes;    population health;    telehealth;    continuous glucose monitoring;   

DOI  :  10.3389/fendo.2023.1063290

 received in 2022-10-06, accepted in 2023-01-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveRemote patient monitoring (RPM) holds potential to enable more individualized and effective care for patients with type 1 diabetes (T1D), but requires population analytics to focus limited clinical resources on patients most in need. We explored the feasibility of RPM from patient and provider standpoints using a commercially available data analytic platform (glooko Population Health) among a cohort of youth with T1D.Study designPatients aged 1-20 years with established T1D (≥12 months) and CGM use (≥3 months) were recruited to participate. Participants’ CGM devices were connected to the glooko app and linked to the research team’s glooko account during a one-month baseline period. This was followed by a six-month intervention period during which participants with >15% of glucose values >250 mg/dl or >5% of values <70 mg/dl each month were contacted with personalized diabetes management recommendations. Participants were surveyed about their experiences, and effects on glycemic control were estimated via change in glucose management indicator (GMI) generated from CGM data at baseline and completion. Changes in time spent within various glucose ranges were also evaluated, and all glycemic metrics were compared to a non-randomized control group via difference-in-difference regression, adjusting for baseline characteristics.ResultsRemote data-sharing was successful for 36 of 39 participants (92%). Between 33%-66% of participants merited outreach each month, and clinician outreach required a median of 10 minutes per event. RPM was reported to be helpful by 94% of participants. RPM was associated with a GMI change of -0.25% (P=0.047) for the entire cohort, and stratified analysis revealed greatest treatment effects among participants with baseline GMI of 8.0-9.4% (GMI change of -0.68%, P=0.047; 19.84% reduction in time spent >250 mg/dl, P=0.005).ConclusionsThis study demonstrates the feasibility of RPM for patients with T1D using a commercially available population health platform, and suggests that RPM with clinician-initiated outreach may be particularly beneficial for patients with suboptimal glycemic control at entry. However, larger randomized studies are needed to fully explore the glycemic impact of RPM.Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT04696640, identifier NCT04696640.

【 授权许可】

Unknown   
Copyright © 2023 Crossen, Romero, Lewis and Glaser